Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481261 | 0.88 | MAPK1 (0.41) | MAPK1USP2SMN1; SMN2MAPTLMNA | |
| SCHEMBL4478376 | 0.87 | MAPK1 (0.41) | MAPK1USP2SMN1; SMN2MAPTLMNA | |
| SCHEMBL4467448 | 0.87 | MEN1 (0.41) | MAPK1USP2SMN1; SMN2MAPTLMNA | |
| SCHEMBL4483470 | 0.86 | ALDH1A1 (0.41) | MAPK1USP2SMN1; SMN2MAPTLMNA | |
| SCHEMBL30659464 | 0.82 | MAPK1 (0.50) | MAPK1USP2SMN1; SMN2MAPTLMNA | |
| SCHEMBL4479719 | 0.82 | MAPK1 (0.50) | MAPK1USP2SMN1; SMN2MAPTLMNA | |
| SCHEMBL4171901 | 0.82 | USP2 (0.43) | USP2SMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL5727630 | 0.75 | MAPT (0.49) | MAPK1SMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL12110031 | 0.73 | MAPK1 (0.42) | MAPK1USP2SMN1; SMN2MAPTGPR119 | |
| SCHEMBL1294281 | 0.73 | ESR2 (0.43) | MAPK1USP2SMN1; SMN2MAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123251-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-8377931-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20090325950-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-31 | — | — | US | disclosed |
| CN-100429206-C | Benzo 58743oxazine derivatives as 5-HT6 modulators and uses thereof | HOFFMANN LA ROCHE (CH) | 2008-10-29 | — | — | CN | disclosed |
| EP-1506179-B1 | BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2006-01-25 | — | — | EP | disclosed |
| CN-1653054-A | Benzoxazine derivatives as 5-HT 6 modulators and uses thereof | HOFFMANN LA ROCHE (CH) | 2005-08-10 | — | — | CN | disclosed |
| US-20050130962-A1 | Benzoxazine derivatives and uses thereof | BERGER JACOB (US) | 2005-06-16 | — | — | US | disclosed |
| US-6867204-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1506179-A1 | BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20030232825-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2003-12-18 | — | — | US | disclosed |
| WO-2003095434-A1 | BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325950-A1 | Benzoxazine derivatives and uses thereof | F12, CYP4X1, CYP3A5 | MAPK1 2055/4885USP2 4159/4885SMN1; SMN2 2523/4885 |
| US-20050130962-A1 | Benzoxazine derivatives and uses thereof | F12, HAX1, CYP4X1 | MAPK1 2324/4885USP2 4130/4885SMN1; SMN2 2602/4885 |
| US-20030232825-A1 | Benzoxazine derivatives and uses thereof | CYP3A5, CYP4X1, XDH | MAPK1 2378/4885USP2 3986/4885SMN1; SMN2 3073/4885 |
| US-20130123251-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | F12, CYP4X1, CYP3A5 | MAPK1 2055/4885USP2 4159/4885SMN1; SMN2 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.